SOPHiA GENETICS (NASDAQ:SOPH) Insider Zhenyu Xu Sells 3,706 Shares

Key Points

• Insider Zhenyu Xu sold multiple blocks of SOPH stock under a pre-arranged Rule 10b5-1 plan to cover tax withholding—about 18,564 shares across March–April (including 3,706 shares on April 10), trimming his stake to 636,510 shares (~$2.98M), a 0.58% decrease.
• SOPHiA GENETICS missed quarterly EPS (loss of $0.28 vs. $0.20 expected) and showed weak profitability (ROE -50.6%, net margin -44.22%), though revenue of $21.71M slightly beat estimates.
• The stock trades near $4.96 with a market cap of $339.7M, a 12‑month range of $2.58–$5.70, and a consensus analyst price target of $7.00 amid mixed ratings (two Buys, one Sell).

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) insider Zhenyu Xu sold 3,706 shares of the stock in a transaction dated Friday, April 10th. The stock was sold at an average price of $4.68, for a total transaction of $17,344.08. Following the sale, the insider owned 636,510 shares of the company's stock, valued at $2,978,866.80. This trade represents a 0.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Zhenyu Xu also recently made the following trade(s):

• On Monday, April 13th, Zhenyu Xu sold 4,414 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.76, for a total transaction of $21,010.64.
• On Thursday, April 9th, Zhenyu Xu sold 1,936 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.74, for a total transaction of $9,176.64.
• On Wednesday, April 8th, Zhenyu Xu sold 2,800 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.84, for a total transaction of $13,552.00.
• On Tuesday, April 7th, Zhenyu Xu sold 2,400 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.87, for a total transaction of $11,688.00.
• On Monday, April 6th, Zhenyu Xu sold 2,700 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.85, for a total transaction of $13,095.00.
• On Thursday, March 19th, Zhenyu Xu sold 608 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.78, for a total transaction of $2,906.24.

SOPHiA GENETICS Price Performance

NASDAQ:SOPH traded up $0.11 during mid-day trading on Tuesday, reaching $4.96. 148,768 shares of the company were exchanged, compared to its average volume of 183,135. SOPHiA GENETICS SA has a 12 month low of $2.58 and a 12 month high of $5.70. The company has a fifty day moving average of $4.74 and a 200 day moving average of $4.71. The company has a quick ratio of 1.84, a current ratio of 1.96 and a debt-to-equity ratio of 1.01. The stock has a market cap of $339.71 million, a PE ratio of -9.73 and a beta of 1.04.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last issued its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.08). SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%.The company had revenue of $21.71 million for the quarter, compared to the consensus estimate of $21.20 million. On average, research analysts anticipate that SOPHiA GENETICS SA will post -0.96 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on SOPH shares. Weiss Ratings reissued a "sell (d-)" rating on shares of SOPHiA GENETICS in a report on Thursday, January 22nd. Guggenheim increased their price objective on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a "buy" rating in a report on Monday, January 26th. Finally, BTIG Research reissued a "buy" rating and set a $7.00 price objective on shares of SOPHiA GENETICS in a report on Tuesday, March 3rd. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $7.00.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. XTX Topco Ltd bought a new position in shares of SOPHiA GENETICS in the 4th quarter valued at about $55,000. Quadrature Capital Ltd bought a new position in shares of SOPHiA GENETICS in the 4th quarter valued at about $54,000. Archon Capital Management LLC boosted its stake in shares of SOPHiA GENETICS by 3.4% in the 4th quarter. Archon Capital Management LLC now owns 441,413 shares of the company's stock valued at $2,061,000 after purchasing an additional 14,342 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of SOPHiA GENETICS by 169.5% in the 4th quarter. Renaissance Technologies LLC now owns 83,000 shares of the company's stock valued at $388,000 after purchasing an additional 52,200 shares during the last quarter. Finally, Polen Capital Management LLC bought a new position in shares of SOPHiA GENETICS in the 4th quarter valued at about $102,000. Institutional investors own 31.59% of the company's stock.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.